Table 1 Baseline characteristics
Patient Characteristic | AP (n = 73) | AG (n = 84) | p-value |
|---|---|---|---|
Median age, years (range) | 49 (33–65) | 50.5 (28–70) | 0.647 |
Median follow-up, months | 26.3 | 23.3 | 0.472 |
Amenorrhea | 0.581 | ||
Premenopausal | 29 (39.7) | 36 (42.9) | |
Postmenopausal | 44 (60.3) | 48 (57.1) | |
Number of metastatic organ sites | 0.014* | ||
<2 | 15 (20.5) | 6 (7.1) | |
≥2 | 58 (79.5) | 78 (92.9) | |
Metastatic sites | |||
Visceral | 59 (80.8) | 69 (82.1) | 0.832 |
Lung | 40 (54.8) | 39 (46.4) | 0.296 |
Liver | 27 (37.0) | 48 (57.1) | 0.012* |
Non-visceral | 14 (19.2) | 15 (17.9) | 0.832 |
Subgroups | 0.370 | ||
Luminal type | 46 (63) | 61 (72.6) | |
HER-2 positive | 8 (11) | 10 (11.9) | |
Triple-negative | 16 (21.9) | 12 (14.3) | |
Unknown | 3 (4.1) | 1 (1.2) | |
Lines of chemotherapy | 0.012* | ||
First line | 36 (49.3) | 59 (70.2) | |
Second line | 28 (38.4) | 15 (17.9) | |
Third line or more line | 9 (12.3) | 10 (11.9) | |
Prior chemotherapy | |||
Anthracycline | 57 (78.1) | 68 (81.0) | 0.66 |
Taxanes | 43 (58.1) | 55 (65.5) | 0.40 |
